AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19438864 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 388
Study 17519902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (IV‐MO)
Number of subjects: 25
Study 17519902 — intervention group
Group type: COMPARATOR
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 25
Study 15351192 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg once daily
Number of subjects: 3825
Study 15351192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3825
Study 12714828 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (60-U/kg bolus and 12-U/kg/h infusion for 72 hours)
Number of subjects: 12142
Study 12714828 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (not specified dosage)
Number of subjects: 12142
Study 9639082 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors (SRIs)
Number of subjects: 40
Study 9639082 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 40
Study 9639082 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy
Number of subjects: 40
Study 8142329 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 6
Study 8142329 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented Milk (FM)
Number of subjects: 6
Study 2659136 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose polyoestradiol phosphate (PEP) 160 mg
Number of subjects: 200
Study 2659136 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low dose acetosalicylic acid (ASA) 75 mg
Number of subjects: 200
Study 2659136 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 200
Study 5312233 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 25
Study 5312233 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 25
Study 31462261 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended invitation highlighting benefits of early detection and prevention of lung disease (n=2194)
Number of subjects: 4407
Study 31462261 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation describing the content of the general health check (n=2213)
Number of subjects: 4407
Study 31462261 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 4407
Study 28833832 — intervention group
Group type: EXPERIMENTAL
Intervention: EtG-based contingency management (CM) intervention for alcohol abstinence and addiction treatment attendance for 12 weeks
Number of subjects: 40
Study 26143297 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 18
Study 23429161 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety floors
Number of subjects: 30
Study 23429161 — intervention group
Group type: COMPARATOR
Intervention: Traditional institutional grade floor
Number of subjects: 30
Study 23429161 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety floors (low BMI males)
Number of subjects: 30
Study 21228137 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal measles vaccine (Moraten)
Number of subjects: 48
Study 21228137 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous measles vaccine (Moraten)
Number of subjects: 48
Study 18304317 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 176
Study 18304317 — intervention group
Group type: COMPARATOR
Intervention: Flat insoles
Number of subjects: 176
Study 18304317 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 176
Study 18304317 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention of foot orthoses and physiotherapy
Number of subjects: 176
Study 16723785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilsicainide (Pil) 150 mg/day
Number of subjects: 60
Study 16723785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline (Cib) 300 mg/day
Number of subjects: 60
Study 15251867 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (ergometer cycling 30-40 min/day, including at least 20 min at 75% Vo(2 max), 5 days/week for 3 months)
Number of subjects: 14
Study 15251867 — intervention group
Group type: COMPARATOR
Intervention: Sedentary schedule
Number of subjects: 14
Study 11421998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11421998 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (1 mg kg‐1)
Number of subjects: 12
Study 11421998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (10 mg kg‐1)
Number of subjects: 12
Study 9045280 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-aortic balloon support
Number of subjects: 0
Study 9045280 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8343611 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolrestat
Number of subjects: 372
Study 8343611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 8343611 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolrestat (switched from placebo)
Number of subjects: 372
Study 8343611 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to tolrestat)
Number of subjects: 372
Study 3511650 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 360
Study 3511650 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 360
Study 29680321 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (5 × 5 Gy plus 1 × 4 Gy boost)
Number of subjects: 51
Study 29680321 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation (50.4 Gy in 28 fractions plus 3 × 1.8 Gy boost and 5‐fluorouracil with leucovorin bolus)
Number of subjects: 51
Study 27492908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior intervention (eliminate all exercise and minimize steps to 5000 or less steps/d for 1 week)
Number of subjects: 39
Study 27492908 — intervention group
Group type: COMPARATOR
Intervention: Control group (continue normal physical activity levels for 1 week)
Number of subjects: 39
Study 25549517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrusive force of 100 g delivered from mini-implants for 6 months
Number of subjects: 16
Study 25549517 — intervention group
Group type: COMPARATOR
Intervention: No orthodontic treatment (control group)
Number of subjects: 16
Study 23413535 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive educative nursing intervention incorporating blood pressure education, monitoring, goal setting and reinforcement.
Number of subjects: 118
Study 23413535 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 118
Study 20837952 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 1A: Irinotecan 20 mg/m(2)/d intravenously for 5 days at weeks 1, 2, 4, and 5 with vincristine 1.5 mg/m(2) on day 1 of weeks 1, 2, 4, and 5
Number of subjects: 92
Study 20837952 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 1B: Irinotecan 50 mg/m(2)/d intravenously for 5 days at weeks 1 and 4 with vincristine as in regimen 1A
Number of subjects: 92
Study 18443034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 500 mg
Number of subjects: 12
Study 15983224 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (0.8 pmol · kg‐1 · min‐1 from ‐30 to 240 min)
Number of subjects: 9
Study 15983224 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg intravenously from ‐30 to ‐15 min) with GLP-1
Number of subjects: 9
Study 15983224 — intervention group
Group type: COMPARATOR
Intervention: GLP-1
Number of subjects: 9
Study 15983224 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin with GLP-1
Number of subjects: 9
Study 15983224 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 9
Study 12669484 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 0
Study 11136881 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. gold (n=114)
Number of subjects: 419
Study 11136881 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate (MTX; n=118)
Number of subjects: 419
Study 11136881 — intervention group
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine (HCQ; n=120)
Number of subjects: 419
Study 11136881 — intervention group
Group type: COMPARATOR
Intervention: NSAID only (n=67)
Number of subjects: 419
Study 11136881 — intervention group
Group type: EXPERIMENTAL
Intervention: SAARDs (combined; n=352)
Number of subjects: 419
Study 9340928 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive MIOL (3M, type 815LE)
Number of subjects: 0
Study 9340928 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive MIOL (Allergan, type Array SSM 26NB)
Number of subjects: 0
Study 1440118 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL 0.12% chlorhexidine gluconate (Peridex, Procter & Gamble)
Number of subjects: 76
Study 1440118 — intervention group
Group type: COMPARATOR
Intervention: 10 mL placebo
Number of subjects: 76
Study 3818052 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding screw plate
Number of subjects: 104
Study 3818052 — intervention group
Group type: COMPARATOR
Intervention: Four AO cancellous bone screws
Number of subjects: 104
Study 31403610 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g·d for 7 days)
Number of subjects: 14
Study 31403610 — intervention group
Group type: COMPARATOR
Intervention: Calcium lactate supplementation (placebo)
Number of subjects: 14
Study 29056249 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 23
Study 29056249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29056249 — intervention group
Group type: COMPARATOR
Intervention: Rituximab and Placebo
Number of subjects: 23
Study 26888096 — intervention group
Group type: EXPERIMENTAL
Intervention: Para (1000 mg paracetamol)
Number of subjects: 40
Study 26888096 — intervention group
Group type: EXPERIMENTAL
Intervention: Para‐Caf (1000 mg paracetamol/130 mg caffeine)
Number of subjects: 40
Study 23856296 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3480 50 mg
Number of subjects: 30
Study 23856296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22223618 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (NARI)
Number of subjects: 0
Study 22223618 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (SSRI)
Number of subjects: 0
Study 20494234 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity promotion programs targeting older adults (aged >=60 years)
Number of subjects: 576
Study 20494234 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity promotion programs targeting obese individuals
Number of subjects: 576
Study 20494234 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity promotion programs targeting current cigarette smokers
Number of subjects: 576
Study 18580179 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta‐tetrahydrocannabinol‐standardized cannabis extract
Number of subjects: 18
Study 18580179 — intervention group
Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 18
Study 15752944 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi (Angiotensin-Converting Enzyme Inhibitor)
Number of subjects: 23
Study 15752944 — intervention group
Group type: COMPARATOR
Intervention: ARB (Angiotensin II Receptor Blocker)
Number of subjects: 23
Study 12834674 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas permeable (RGP) contact lenses
Number of subjects: 428
Study 12834674 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 428
Study 9436721 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 Dysport units
Number of subjects: 75
Study 9436721 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 Dysport units
Number of subjects: 75
Study 9436721 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 Dysport units
Number of subjects: 75
Study 9436721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 7645935 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 73
Study 7645935 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (sonography)
Number of subjects: 73
Study 2971131 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms hANP (Bissendorf peptide)
Number of subjects: 8
Study 2971131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29445269 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin oral controlled absorption system (OCAS)
Number of subjects: 81
Study 29445269 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin OCAS
Number of subjects: 81
Study 27218270 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 R46L carriers
Number of subjects: 103083
Study 27218270 — intervention group
Group type: COMPARATOR
Intervention: PCSK9 R46L noncarriers
Number of subjects: 103083
Study 27218270 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 R46L heterozygotes
Number of subjects: 103083
Study 24803474 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 1223
Study 24803474 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 1223
Study 24803474 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine + Antioxidants
Number of subjects: 1223
Study 24803474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1223
Study 23470848 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 2738
Study 23470848 — intervention group
Group type: COMPARATOR
Intervention: Trivalent influenza vaccines (TIV)
Number of subjects: 2738
Study 21707573 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05% (CP) twice weekly alternating with ketoconazole shampoo 2% (KC) twice weekly
Number of subjects: 0
Study 21707573 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05% (CP) twice weekly (C2)
Number of subjects: 0
Study 21707573 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05% (CP) four times weekly alternating with ketoconazole shampoo 2% (KC) twice weekly (C4+K2)
Number of subjects: 0
Study 21707573 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole shampoo 2% (KC) twice weekly (K2)
Number of subjects: 0
Study 20151523 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake during pregnancy
Number of subjects: 0
Study 20151523 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for anesthesiologists and obstetrician-gynecologists
Number of subjects: 0
Study 16721394 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Bifidobacterium animalis subsp lactis BB-12) at 10(11) CFU/day
Number of subjects: 71
Study 16721394 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Bifidobacterium animalis subsp lactis BB-12)
Number of subjects: 71
Study 16721394 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-431)
Number of subjects: 71
Study 16721394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 15569389 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital lectures
Number of subjects: 0
Study 15569389 — intervention group
Group type: COMPARATOR
Intervention: Live lectures
Number of subjects: 0
Study 11326768 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐CARE plus CAST
Number of subjects: 341
Study 11326768 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐CARE only
Number of subjects: 341
Study 11326768 — intervention group
Group type: COMPARATOR
Intervention: Intervention as usual
Number of subjects: 341
Study 9155956 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum A toxin (Dysport) - 120 mU injected into six different sites on one palm
Number of subjects: 11
Study 9155956 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (placebo) injected into the other palm
Number of subjects: 11
Study 8123390 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide exposure for 30, 60, or 120 min with normoventilation or hypoventilation
Number of subjects: 36
Study 8123390 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoventilation
Number of subjects: 36
Study 8123390 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoventilation
Number of subjects: 36
Study 8123390 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoventilation after 1 or 2 h of nitrous oxide exposure
Number of subjects: 36
Study 3909239 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Gy 3 times a day to a total of 84 Gy
Number of subjects: 168
Study 3909239 — intervention group
Group type: COMPARATOR
Intervention: 2 Gy once a day to a total of 64 Gy
Number of subjects: 168
Study 30177994 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus standard of care (SOC)
Number of subjects: 485
Study 30177994 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 485
Study 30177994 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus SOC
Number of subjects: 485
Study 30177994 — intervention group
Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 485
Study 27010377 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐TMS at frequencies of 5 Hz and 10 Hz for 15 minutes daily for 20 days combined with standard therapy (ST) of 1 hour daily.
Number of subjects: 20
Study 27010377 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST) of 1 hour daily for 20 days.
Number of subjects: 20
Study 23579578 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser ablative surgery with bowel resection (study group, n = 76)
Number of subjects: 203
Study 23579578 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser ablative surgery without bowel resection (control group, n = 127)
Number of subjects: 203
Study 23579578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (study and control)
Number of subjects: 203
Study 22464340 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological treatment (additional infliximab)
Number of subjects: 258
Study 22464340 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (additional sulfasalazine and hydroxychloroquine)
Number of subjects: 258
Study 19589691 — intervention group
Group type: EXPERIMENTAL
Intervention: New digital monitoring protocol for chest tube removal
Number of subjects: 166
Study 19589691 — intervention group
Group type: COMPARATOR
Intervention: Traditional protocol using visual and subjective assessment of air leak
Number of subjects: 166
Study 17991759 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 10
Study 17991759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17530097 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HSP60 IgG in Group A preoperatively
Number of subjects: 45
Study 17530097 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HSP60 IgG in Group A postoperatively
Number of subjects: 45
Study 17530097 — intervention group
Group type: COMPARATOR
Intervention: Anti-HSP60 IgG in Group B preoperatively
Number of subjects: 45
Study 17530097 — intervention group
Group type: COMPARATOR
Intervention: Anti-HSP60 IgG in Group B postoperatively
Number of subjects: 45
Study 14736626 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face delivered treatment
Number of subjects: 66
Study 14736626 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet delivered treatment
Number of subjects: 66
Study 14736626 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 66
Study 11039470 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic porcine secretin (1 CU/kg)
Number of subjects: 12
Study 11039470 — intervention group
Group type: COMPARATOR
Intervention: Synthetic porcine secretin (0.2 microg/kg)
Number of subjects: 12
Study 9187783 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms.kg‐1.min‐1 propofol
Number of subjects: 41
Study 9187783 — intervention group
Group type: COMPARATOR
Intervention: 0.25 microgram.kg‐1.min‐1 midazolam
Number of subjects: 41
Study 1343377 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (280 mg/day)
Number of subjects: 72
Study 1343377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 1343377 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 72
Study 1343377 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who abstained from alcohol
Number of subjects: 72
Study 3905343 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/ml anhydrous theophylline dissolved in 20% pure alcohol, loading dose of 5 mg/kg and then 1.25 mg/kg every 6 h
Number of subjects: 40
Study 3905343 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 31370751 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% 2‐chloroprocaine (group C, n = 40)
Number of subjects: 80
Study 31370751 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine (group L, n = 40)
Number of subjects: 80
Study 25803602 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing an educational song
Number of subjects: 18
Study 25803602 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not sing the song)
Number of subjects: 18
Study 22684154 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally-invasive surfactant therapy (MIST)
Number of subjects: 61
Study 22684154 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 61
Study 21675494 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin cream 5%
Number of subjects: 75
Study 21675494 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone cream 0.1%
Number of subjects: 75
Study 19704057 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR 30 mg intramuscularly in monthly intervals
Number of subjects: 85
Study 19704057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 19704057 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Number of subjects: 85